At Genemed Biotechnologies, Inc., we incorporate quality from the inside out, from our dedicated employees and efficient operations to our finished products. We are cGMP-compliant and ISO-13485:2003 certified. Every part of our facility, systems, and processes are continuously monitored to ensure that we meet the highest standards of quality and customer satisfaction.
We have been successfully conducting business for over 20 years in South San Francisco, and our experienced and highly skilled staff is committed to consistently going above and beyond to ensure our customers' needs are met. Our achievements have been built upon our strong corporate values of teamwork, innovation, efficiency and integrity.
A History of Delivering Superior Service
Genemed Biotechnologies, Inc. was founded in 1987 and is located in the center of the South San Francisco Biotechnology community. For over 15 years, Genemed has been providing outstanding contract development and manufacturing services for well-established pharmaceutical and diagnostic companies. In 2009, to continue with our tradition of delivering excellent service, we launched our very own product lines to better serve the needs of the Biotechnology community.
Advances in IHC and ISH techniques in the past decade, especially their use on formalin-fixed paraffin-embedded tissues and discovery of newer bio-molecules, result in their increasingly valuable role in surgical pathology, and increased the demands from surgical pathology services. Nowadays, in the context of a detailed morphological analysis and differential diagnosis based on the H&E staining, IHC and ISH have become major parts of the practice of diagnostic surgical pathology worldwide to help in rendering a diagnosis, classification of tumors, prediction of the likely origin of a carcinoma, demonstration of micro metastases, provision of prognostic information, justification of expensive targeted therapy (companion diagnosis), and demonstration of microorganisms. Today, we are in an era of translational crossroads for biomarkers and personalized medicine, and IHC and ISH will remain center stage in the demonstration of newer bio-markers and their applications.
Genemed's goal is to provide superior products and services that support both academic and commercial endeavors in the area of in-vitro diagnostics and fundamental scientific research.
Mission Statement
Genemed provides cancer and infectious disease diagnostic reagents for different instruments and technology platforms. We also provide service to our partners to accelerate their IVD product development and commercialization.
We create smarter and user-friendly diagnostic tools and solutions by applying our expertise in product design and manufacturing processes. Genemed strives to go above and beyond to meet every customer need with our personalized service. We are passionate at applying innovative technology and breakthrough scientific discoveries to improve product quality and reliability which ensure accurate diagnoses and enhanced patient care.
We pride ourselves in conducting business in a fair and ethical manner. Genemed values our employees by promoting a learning environment with professional growth.
Management
Our executive team at Genemed Biotechnologies, Inc. has extensive management experience in the development and manufacture of biological and diagnostic products. Their areas of expertise include manufacturing and technical operations, quality control and quality assurance, R&D, validation, and business development.
Key members of our executive team include:
Dean Tsao, Ph.D., Chairman
Dr. Tsao founded Genemed Biotechnologies, Inc. in 1987. Prior to his position at Genemed Biotechnologies Inc., Dr. Tsao was also the founder and President of Zymed Laboratories and Genemed Synthesis Inc. Zymed Laboratories, founded in 1980, provided antibody based immunochemicals for cancer research and cancer diagnostic applications. The company was acquired by Invitrogen in 2005. Genemed Synthesis Inc, founded in 1995, provided custom DNA and Peptides synthesis services. The company was acquired by Genomic Resources Inc. in 2007.
During the late 80s and early 90s, Dr. Tsao was a visiting professor at the Chinese Academy of Preventative Medicine, Beijing, adjunct professor at Chang Gung Medical College, and visiting scientist at Veterans General Hospital, Taiwan.
Dr. Tsao holds a doctorate in biochemistry from Colorado State University and a B.S. in Agricultural Chemistry from National Chung-Hsing University, Taiwan. He has authored more than thirty scientific articles and three patents and has been honored with the American Heart Association Post-Doctorate Fellowship. He also served in College of Natural Sciences External Advisory Committee of CSU.
Peter Luu, President
Peter has over 20 years of management expertise in the biotechnology and medical device industries, with a degree from U.C. Berkeley.
Rina Wu DeCamillis, M.D., Ph.D., VP of R&D and Operations
Rina has over 10 years of experience in design and development immunohistochemistry (IHC) assays, in situ hybridization (ISH) assays in single and multiplexed, manual and automated platforms. She has both a M.D. and Ph. D. with numerous publications and a patent on CISH.
